Protein / target
Tubulin beta chain
Protein at a glance
Biological role
Structural constituent of cytoskeleton
Strongest disease association
Complex cortical dysplasia with other brain malformations 6
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers.
View complete UniProt function annotationHide complete annotation
Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin
Subcellular location
Domains and Gene Ontology detail (38)Hide
Gene Ontology
- Cazurophil granule lumen
- Ccell body
- Cciliary tip
- Ccilium
- Ccytoplasm
- Ccytoplasmic ribonucleoprotein granule
- Ccytoskeleton
- Ccytosol
- Cextracellular exosome
- Cextracellular region
- Cintercellular bridge
- Cmembrane raft
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell-cycle regulation
- ·mitotic cell cycle
- ·Regulation of PLK1 Activity at G2/M Transition
Synaptic signalling
- ·regulation of synapse organization
View underlying pathways (9)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
25 medicines meet Open Targets' target-level approved-medicine definition; the 9 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Tubulin inhibitor
Indicated for Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms
Tubulin inhibitor
Indicated for Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms
Tubulin inhibitor
Indicated for Uterine Cervical Neoplasms, Neoplasms
Tubulin inhibitor
Indicated for Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Tubulin inhibitor
Indicated for Carcinoma, Transitional Cell, Urologic Neoplasms, Neoplasms
View all 13 targeting drugsHide
Tubulin inhibitor
Indicated for Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms
Tubulin inhibitor
Tubulin disrupting agent
Tubulin inhibitor
Tubulin inhibitor
Indicated for Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasms
Tubulin stabiliser
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene TUBB
Gene-level evidence surfaced through the gene TUBBthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
88 compounds recorded · 25 approved · 62 in clinical development · 1 earlier-stage
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 6 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
- Trial results posted
A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer
- Trial results posted
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
- Trial results posted
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- CHMP positive opinion
CHMP positive opinion: Colchicine Agepha Pharma (EMA)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Regulatory approval
Approval: Blenrep (EMA)
- New publicationPembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
- New publicationA randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer.
- New publicationDatopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
- New publicationTisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.